235 related articles for article (PubMed ID: 26346331)
1. Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo.
Zheng K; Li R; Zhou X; Hu P; Zhang Y; Huang Y; Chen Z; Huang M
Int J Nanomedicine; 2015; 10():5327-42. PubMed ID: 26346331
[TBL] [Abstract][Full Text] [Related]
2. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity.
Yuan A; Wu J; Song C; Tang X; Qiao Q; Zhao L; Gong G; Hu Y
J Pharm Sci; 2013 May; 102(5):1626-35. PubMed ID: 23423631
[TBL] [Abstract][Full Text] [Related]
3. A novel tumor targeting drug carrier for optical imaging and therapy.
Li R; Zheng K; Hu P; Chen Z; Zhou S; Chen J; Yuan C; Chen S; Zheng W; Ma E; Zhang F; Xue J; Chen X; Huang M
Theranostics; 2014; 4(6):642-59. PubMed ID: 24723985
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor.
Prakash J; Beljaars L; Harapanahalli AK; Zeinstra-Smith M; de Jager-Krikken A; Hessing M; Steen H; Poelstra K
Int J Cancer; 2010 Apr; 126(8):1966-1981. PubMed ID: 19795464
[TBL] [Abstract][Full Text] [Related]
5. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
[TBL] [Abstract][Full Text] [Related]
7. Tumor Targeting Chemo- and Photodynamic Therapy Packaged in Albumin for Enhanced Anti-Tumor Efficacy.
Zheng K; Liu H; Liu X; Wang Y; Li L; Li S; Xue J; Huang M
Int J Nanomedicine; 2020; 15():151-167. PubMed ID: 32021171
[TBL] [Abstract][Full Text] [Related]
8. Redox-responsive mesoporous selenium delivery of doxorubicin targets MCF-7 cells and synergistically enhances its anti-tumor activity.
Zhao S; Yu Q; Pan J; Zhou Y; Cao C; Ouyang JM; Liu J
Acta Biomater; 2017 May; 54():294-306. PubMed ID: 28267598
[TBL] [Abstract][Full Text] [Related]
9. Albumin-Albumin/Lactosylated Core-Shell Nanoparticles: Therapy to Treat Hepatocellular Carcinoma for Controlled Delivery of Doxorubicin.
Teran-Saavedra NG; Sarabia-Sainz JA; Velázquez-Contreras EF; Ramos-Clamont Montfort G; Pedroza-Montero M; Vazquez-Moreno L
Molecules; 2020 Nov; 25(22):. PubMed ID: 33233564
[TBL] [Abstract][Full Text] [Related]
10. A tumor environment responsive doxorubicin-loaded nanoparticle for targeted cancer therapy.
Zhu Q; Jia L; Gao Z; Wang C; Jiang H; Zhang J; Dong L
Mol Pharm; 2014 Oct; 11(10):3269-78. PubMed ID: 24735448
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor efficacy and attenuated cardiotoxicity of doxorubicin in combination with lycopene liposomes.
Zhu J; Hu Q; Shen S
J Liposome Res; 2020 Mar; 30(1):37-44. PubMed ID: 30741056
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
13. A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging.
Zhou X; Zheng K; Li R; Chen Z; Yuan C; Hu P; Chen J; Xue J; Huang M
Acta Biomater; 2015 Sep; 23():116-126. PubMed ID: 26004218
[TBL] [Abstract][Full Text] [Related]
14. Charge Reversible and Mitochondria/Nucleus Dual Target Lipid Hybrid Nanoparticles To Enhance Antitumor Activity of Doxorubicin.
Song YF; Liu DZ; Cheng Y; Teng ZH; Cui H; Liu M; Zhang BL; Mei QB; Zhou SY
Mol Pharm; 2018 Mar; 15(3):1296-1308. PubMed ID: 29432025
[TBL] [Abstract][Full Text] [Related]
15. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
[TBL] [Abstract][Full Text] [Related]
16. Tumor-pH-Sensitive PLLA-Based Microsphere with Acid Cleavable Acetal Bonds on the Backbone for Efficient Localized Chemotherapy.
Li J; Zhang X; Zhao M; Wu L; Luo K; Pu Y; He B
Biomacromolecules; 2018 Jul; 19(7):3140-3148. PubMed ID: 29883542
[TBL] [Abstract][Full Text] [Related]
17. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
18. Enhanced tumor delivery and antitumor response of doxorubicin-loaded albumin nanoparticles formulated based on a Schiff base.
Li F; Zheng C; Xin J; Chen F; Ling H; Sun L; Webster TJ; Ming X; Liu J
Int J Nanomedicine; 2016; 11():3875-90. PubMed ID: 27574421
[TBL] [Abstract][Full Text] [Related]
19. Nutrition Modulation of Cardiotoxicity and Anticancer Efficacy Related to Doxorubicin Chemotherapy by Glutamine and ω-3 Polyunsaturated Fatty Acids.
Xue H; Ren W; Denkinger M; Schlotzer E; Wischmeyer PE
JPEN J Parenter Enteral Nutr; 2016 Jan; 40(1):52-66. PubMed ID: 25888676
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
